Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform
Posted:
The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.
The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.
Antimicrobial resistance could claim almost two million lives a year by 2050. Now, researchers believe they could use #AI to predict which bugs will become resistant so that we can better prepare.
Read the full article here.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…